Magazine Article | November 1, 2022

Fueling A Focused Drug Development Model

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Developing early and mid stage product candidates — and letting partners handle discovery and commercialization — is the established model for Debiopharm, and one that CEO Bertrand Ducrey doesn’t plan to alter. Founded in 1979 by Rolland-Yves Mauvernay, the company has remained private and in the family: Thierry Mauvernay, son of Rolland-Yves, currently sits on the board and is president of Debiopharm, as well as president of Après-demain, the parent company overseeing Debiopharm’s life sciences activities, as well as separate asset management, philanthropy, and environmentally focused social investing divisions.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader